Characterization of the T-Cell Receptor Repertoire and Immune Microenvironment in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck

Purpose: Squamous cell carcinoma of the head and neck (SCCHN) is a lethal cancer with a suboptimal 5-year overall survival of approximately 50% with surgery and/or definitive chemoradiotherapy. Novel treatments are thus urgently awaited. Immunotherapy with checkpoint blockade has emerged as a promising option for patients with recurrent/metastatic SCCHN; however, it has not been investigated in the curative-intent setting yet. The purpose of this study was to investigate the T-cell receptor repertoire and the tumor microenvironment in tumor tissues of SCCHN patients with locoregionally advanced disease. Experimental Design: We performed T-cell receptor sequencing of tumor tissues from 44 patients with locoregionally advanced SCCHN prior to treatment with definitive chemoradiotherapy and correlated the T-cell clonality and the mRNA expression levels of immune-related genes with clinicopathologic parameters. Results: Clonal expansion of T cells was significantly higher in human papilloma virus (HPV)–negative compared with HPV-positive tumors, signifying more robust antigen presentation in HPV-negative tumors. The latter was supported by the higher percentage of HPV-negative tumors expressing HLA-A protein compared with HPV-positive tumors (P = 0.049). Higher GRZB levels correlated significantly with longer recurrence-free survival (log-rank, P = 0.003) independent of tumor size, nodal stage, and HPV status. Conclusions: Our findings support clonal expansion of T cells in SCCHN patients with locoregionally advanced disease and imply differences in the antigen presentation capacity between HPV-negative and HPV-positive tumors. Elevated GRZB mRNA levels may also serve as a favorable and independent predictor of outcome in SCCHN patients treated with chemoradiotherapy. These data provide rationale for the introduction of immunotherapeutic approaches in the curative-intent setting. Clin Cancer Res; 23(16); 4897–907. ©2017 AACR.

[1]  Yusuke Nakamura,et al.  Low T-cell Receptor Diversity, High Somatic Mutation Burden, and High Neoantigen Load as Predictors of Clinical Outcome in Muscle-invasive Bladder Cancer. , 2016, European urology focus.

[2]  P. Hammerman,et al.  Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer , 2016, British Journal of Cancer.

[3]  J. Lunceford,et al.  Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. , 2016, The Lancet. Oncology.

[4]  R. Hitt,et al.  Targeted Therapy in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (LA-R/M HNSCC) , 2016, Cancers.

[5]  P. Moore,et al.  A Phase I, open-label, dose escalation study of MGA271 in combination with pembrolizumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck, or squamous cell non-small cell lung cancer , 2015, Journal of Immunotherapy for Cancer.

[6]  P. Moore,et al.  A Phase I, open-label, dose escalation study of MGA271 in combination with ipilimumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck or non-small cell lung cancer , 2015, Journal of Immunotherapy for Cancer.

[7]  D. Hayes,et al.  Genetic Landscape of Human Papillomavirus-Associated Head and Neck Cancer and Comparison to Tobacco-Related Tumors. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  S Miyano,et al.  Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients , 2015, Bone Marrow Transplantation.

[9]  R. Ferris,et al.  CTLA-4⁺ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis. , 2015, Cancer research.

[10]  Yusuke Nakamura,et al.  Characterization of T cell repertoire of blood, tumor, and ascites in ovarian cancer patients using next generation sequencing , 2015, Oncoimmunology.

[11]  M. Mcnamara,et al.  OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal , 2015, Front. Oncol..

[12]  Sonali M. Smith,et al.  Highly clonal regulatory T-cell population in follicular lymphoma – inverse correlation with the diversity of CD8+ T cells , 2015, Oncoimmunology.

[13]  A. Näsman,et al.  Reduced Expression of the Antigen Processing Machinery Components TAP2, LMP2, and LMP7 in Tonsillar and Base of Tongue Cancer and Implications for Clinical Outcome , 2015, Translational oncology.

[14]  J. Schoenfeld.  Immunity in Head and Neck Cancer , 2015, Cancer Immunology Research.

[15]  Yusuke Nakamura,et al.  Quantitative T cell repertoire analysis by deep cDNA sequencing of T cell receptor α and β chains using next-generation sequencing (NGS) , 2014, Oncoimmunology.

[16]  Christopher D. Brown,et al.  Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas , 2014, Clinical Cancer Research.

[17]  yang-xin fu,et al.  Radiation and anti-PD-L1 antibody combinatorial therapy induces T cell-mediated depletion of myeloid-derived suppressor cells and tumor regression , 2014, Oncoimmunology.

[18]  N. Hacohen,et al.  HLA-Binding Properties of Tumor Neoepitopes in Humans , 2014, Cancer Immunology Research.

[19]  R. Weichselbaum,et al.  Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. , 2014, The Journal of clinical investigation.

[20]  Jacques Ferlay,et al.  Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  E. King,et al.  Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer , 2013, British Journal of Cancer.

[22]  R. Ferris,et al.  Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients , 2013, British Journal of Cancer.

[23]  C. Rödel,et al.  Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer , 2013, British Journal of Cancer.

[24]  T. Nyberg,et al.  CD8+ and CD4+ tumour infiltrating lymphocytes in relation to human papillomavirus status and clinical outcome in tonsillar and base of tongue squamous cell carcinoma. , 2013, European journal of cancer.

[25]  S. Demaria,et al.  Combining radiotherapy and cancer immunotherapy: a paradigm shift. , 2013, Journal of the National Cancer Institute.

[26]  S. Demaria,et al.  Role of T lymphocytes in tumor response to radiotherapy , 2012, Front. Oncol..

[27]  E. Sturgis,et al.  Human papillomavirus as a marker of the natural history and response to therapy of head and neck squamous cell carcinoma. , 2012, Seminars in radiation oncology.

[28]  H. Friess,et al.  B7-H3 and Its Role in Antitumor Immunity , 2010, Clinical & developmental immunology.

[29]  Marc S. Cortese,et al.  HPV-16 E5 down-regulates expression of surface HLA class I and reduces recognition by CD8 T cells. , 2010, Virology.

[30]  Hui Li,et al.  HPV16E7 mediates HADC chromatin repression and downregulation of MHC class I genes in HPV16 tumorigenic cells through interaction with an MHC class I promoter. , 2006, Biochemical and biophysical research communications.

[31]  R. Ferris,et al.  Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck. , 2005, Cancer research.

[32]  B. Fox,et al.  OX40 signaling in head and neck squamous cell carcinoma: Overcoming immunosuppression in the tumor microenvironment. , 2016, Oral oncology.

[33]  V. Budach,et al.  CD8+ tumour‐infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German cancer consortium radiation oncology group (DKTK‐ROG) , 2016, International journal of cancer.

[34]  yang-xin fu,et al.  Immunotherapy and tumor microenvironment. , 2016, Cancer letters.